308 related articles for article (PubMed ID: 16238680)
1. The effect of statin therapy on plasma high-density lipoprotein cholesterol levels is modified by paraoxonase-1 in patients with familial hypercholesterolaemia.
Himbergen TM; van Tits LJ; Voorbij HA; de Graaf J; Stalenhoef AF; Roest M
J Intern Med; 2005 Nov; 258(5):442-9. PubMed ID: 16238680
[TBL] [Abstract][Full Text] [Related]
2. Antioxidant effect of atorvastatin is independent of PON1 gene T(-107)C, Q192R and L55M polymorphisms in hypercholesterolaemic patients.
Sardo MA; Campo S; Bonaiuto M; Bonaiuto A; Saitta C; Trimarchi G; Castaldo M; Bitto A; Cinquegrani M; Saitta A
Curr Med Res Opin; 2005 May; 21(5):777-84. PubMed ID: 15969877
[TBL] [Abstract][Full Text] [Related]
3. Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial.
Stender S; Schuster H; Barter P; Watkins C; Kallend D;
Diabetes Obes Metab; 2005 Jul; 7(4):430-8. PubMed ID: 15955130
[TBL] [Abstract][Full Text] [Related]
4. Effect of statin therapy on plasma high-density lipoprotein-cholesterol levels is modified by paraoxonase 1 in Chinese patients with coronary heart disease.
Fu R; Sun YM; Su Y; Wu Y; Luan Y
Clin Exp Pharmacol Physiol; 2008 Aug; 35(8):982-3. PubMed ID: 18430057
[TBL] [Abstract][Full Text] [Related]
5. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
[TBL] [Abstract][Full Text] [Related]
6. Effect of short term treatment with simvastatin and atorvastatin on lipids and paraoxonase activity in patients with hyperlipoproteinaemia.
Paragh G; Törocsik D; Seres I; Harangi M; Illyés L; Balogh Z; Kovács P
Curr Med Res Opin; 2004 Aug; 20(8):1321-7. PubMed ID: 15324535
[TBL] [Abstract][Full Text] [Related]
7. Modulating effect of atorvastatin on paraoxonase 1 activity in type 2 diabetic Egyptian patients with or without nephropathy.
Abdin AA; Hassanien MA; Ibrahim EA; El-Noeman Sel-D
J Diabetes Complications; 2010; 24(5):325-33. PubMed ID: 19553142
[TBL] [Abstract][Full Text] [Related]
8. Association between serum paraoxonase (PON1) gene promoter T(-107)C polymorphism, PON1 activity and HDL levels in healthy Sicilian octogenarians.
Campo S; Sardo MA; Trimarchi G; Bonaiuto M; Fontana L; Castaldo M; Bonaiuto A; Saitta C; Bitto A; Manduca B; Riggio S; Saitta A
Exp Gerontol; 2004 Jul; 39(7):1089-94. PubMed ID: 15236768
[TBL] [Abstract][Full Text] [Related]
9. Paraoxonase-1 and linoleic acid oxidation in familial hypercholesterolemia.
van Himbergen TM; van Tits LJ; Hectors MP; de Graaf J; Roest M; Stalenhoef AF
Biochem Biophys Res Commun; 2005 Aug; 333(3):787-93. PubMed ID: 15963464
[TBL] [Abstract][Full Text] [Related]
10. The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study.
Roeters van Lennep HW; Liem AH; Dunselman PH; Dallinga-Thie GM; Zwinderman AH; Jukema JW
Curr Med Res Opin; 2008 Mar; 24(3):685-94. PubMed ID: 18226326
[TBL] [Abstract][Full Text] [Related]
11. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
12. Effect of paraoxonase 1 polymorphisms on the response of lipids and lipoprotein-associated enzymes to treatment with fluvastatin.
Christidis DS; Liberopoulos EN; Kakafika AI; Miltiadous GA; Liamis GL; Kakaidi B; Tselepis AD; Cariolou MA; Elisaf MS
Arch Med Res; 2007 May; 38(4):403-10. PubMed ID: 17416287
[TBL] [Abstract][Full Text] [Related]
13. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
Jones PH; Hunninghake DB; Ferdinand KC; Stein EA; Gold A; Caplan RJ; Blasetto JW;
Clin Ther; 2004 Sep; 26(9):1388-99. PubMed ID: 15531001
[TBL] [Abstract][Full Text] [Related]
14. One-year atorvastatin treatment in hypercholesterolemic patients with or without carotid artery disease.
Avellone G; Di Garbo V; Abruzzese G; Campisi D; De Simone R; Raneli G; Licata G
Int Angiol; 2006 Mar; 25(1):26-34. PubMed ID: 16520721
[TBL] [Abstract][Full Text] [Related]
15. Effect of simvastatin therapy on paraoxonase activity and related lipoproteins in familial hypercholesterolemic patients.
Tomás M; Sentí M; García-Faria F; Vila J; Torrents A; Covas M; Marrugat J
Arterioscler Thromb Vasc Biol; 2000 Sep; 20(9):2113-9. PubMed ID: 10978257
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients.
Bloomfield D; Carlson GL; Sapre A; Tribble D; McKenney JM; Littlejohn TW; Sisk CM; Mitchel Y; Pasternak RC
Am Heart J; 2009 Feb; 157(2):352-360.e2. PubMed ID: 19185645
[TBL] [Abstract][Full Text] [Related]
17. A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial.
Illingworth DR; Crouse JR; Hunninghake DB; Davidson MH; Escobar ID; Stalenhoef AF; Paragh G; Ma PT; Liu M; Melino MR; O'Grady L; Mercuri M; Mitchel YB;
Curr Med Res Opin; 2001; 17(1):43-50. PubMed ID: 11464446
[TBL] [Abstract][Full Text] [Related]
18. hsCRP and HDL effects of statins trial (CHEST): rapid effect of statin therapy on C-reactive protein and high-density lipoprotein levels A clinical investigation.
Ansell BJ; Watson KE; Weiss RE; Fonarow GC
Heart Dis; 2003; 5(1):2-7. PubMed ID: 12549983
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin.
McKenney JM; Davidson MH; Shear CL; Revkin JH
J Am Coll Cardiol; 2006 Nov; 48(9):1782-90. PubMed ID: 17084250
[TBL] [Abstract][Full Text] [Related]
20. Treatment of heterozygous familial hypercholesterolemia: atorvastatin vs simvastatin.
Bo M; Nicolello MT; Fiandra U; Mercadante G; Piliego T; Fabris F
Nutr Metab Cardiovasc Dis; 2001 Feb; 11(1):17-24. PubMed ID: 11383320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
